Latest Breaking News On - Professor zhang hong - Page 1 : comparemela.com

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren s Syndrome

/PRNewswire/ RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced significant.

United statesZhang hongJianmin fangZeng xiaofengRemegen co ltdUnion medical college hospitalNational medical products administrationPrnewswire remegen coRemegen coUniversity first hospitalProfessor zhang hongPeking university firstProfessor zeng xiaofengPeking union medical collegeMultidimensional fatigue inventory

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China
thailand-business-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thailand-business-news.com Daily Mail and Mail on Sunday newspapers.

Hong kongSouth koreaZhang hongUnited statesHainan boaoXie jingyuanRogers yongqing luoDrug administrationShanghai jiao tong university school of medicineUniversity first hospitalPhysician of the department nephrologyWorld congressChina national medical products administrationEverest medicinesBreakthrough therapy designationChief executive officer

Everest Medicines Announces China NMPA s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines Announces China NMPA s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSouth koreaHong kongZhang hongXie jingyuanRogers yongqing luoChina national medical products administrationDrug administrationWhile the companyShanghai jiao tong university school of medicineEuropean unionAmerican society of nephrologyEuropean medicines agencyPhysician of the department nephrologyUniversity first hospital

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

/PRNewswire/ Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and.

South koreaZhang hongHong kongRogers yongqing luoUniversity first hospitalEverest medicinesPharmaceutical administration bureauMacau special administrative regionNew drug applicationChief executive officerProfessor zhang hongPeking university first hospitalAbout nefeconMainland chinaEverest medicineHealth care amp hospitals

Everest Medicines Launches Nefecon in China s Hainan Boao Pilot Zone as a First-in-Disease Therapy for IgA Nephropathy

/PRNewswire/ Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and.

Zhang hongHong kongSouth koreaHainan boao lechengRogers yongqing luoHainan medical products administrationUniversity first hospitalShanghai ruijin hospitalHainan boao lecheng pilot zoneChief executive officerEverest medicineGalactose deficient igaProfessor zhang hongPeking university first hospitalAbout nefeconEverest medicines